Home > Boards > US Listed > Biotechs > Brooklyn ImmunoTherapeutics Inc (BTX)

BTX > "company said it has established a

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
crudeoil24 Member Profile
Member Level 
Followed By 707
Posts 47,393
Boards Moderated 8
Alias Born 12/12/04
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/22/2021 4:57:58 PM
Brooklyn ImmunoTherapeutics Appoints Roger Sidhu, M.D. as Chief Medical Officer GlobeNewswire Inc. - 9/22/2021 10:07:32 AM
Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021 GlobeNewswire Inc. - 9/21/2021 8:30:00 AM
Factor Bioscience Celebrates 10th Anniversary with Grand Opening of ISO Class 7 Cleanroom Facility in Cambridge, Massachusetts PR Newswire (US) - 9/15/2021 8:15:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/14/2021 7:01:22 AM
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Monday, September 20, 2021, at 4:30 PM ET GlobeNewswire Inc. - 9/13/2021 8:00:00 AM
Brooklyn ImmunoTherapeutics to Participate in Grand Opening of Cambridge-Based mRNA Cleanroom Facility Shared with Factor Bioscience GlobeNewswire Inc. - 9/9/2021 8:30:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 8/27/2021 5:46:47 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 8/20/2021 4:46:21 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/20/2021 4:46:05 PM
Brooklyn ImmunoTherapeutics Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum GlobeNewswire Inc. - 8/20/2021 4:15:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/20/2021 1:40:41 PM
Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from August 19, 2021 GlobeNewswire Inc. - 8/20/2021 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/17/2021 5:29:58 PM
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Thursday, August 19, 2021 at 4:30 PM ET GlobeNewswire Inc. - 8/16/2021 4:15:00 PM
Brooklyn ImmunoTherapeutics Announces Second Quarter 2021 Financial Results GlobeNewswire Inc. - 8/16/2021 7:00:00 AM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 8/13/2021 5:06:59 PM
Brooklyn ImmunoTherapeutics to Present at the SNN Virtual Investor Conference on August 18, 2021 GlobeNewswire Inc. - 8/13/2021 2:21:57 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 7/26/2021 4:06:21 PM
Brooklyn Immuno Reports Inducement Grants GlobeNewswire Inc. - 7/23/2021 4:30:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/19/2021 4:06:50 PM
Brooklyn ImmunoTherapeutics completes acquisition of Novellus Therapeutics Seeking Alpha - 7/19/2021 10:22:43 AM
Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics GlobeNewswire Inc. - 7/19/2021 8:00:00 AM
Brooklyn ImmunoTherapeutics Welcomes Jay Sial as Chief Administrative Officer GlobeNewswire Inc. - 7/13/2021 8:15:00 AM
Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021 GlobeNewswire Inc. - 7/12/2021 8:15:00 AM
crudeoil24 Member Level  Thursday, 06/03/21 11:57:00 AM
Re: None
Post # of 297 
BTX > "company said it has established a research and development center in Cambridge, Mass., to pursue its mRNA-based gene editing and cellular therapies.

The company said it has co-located with Factor Bioscience Limited and Novellus Therapeutics Limited, from which Brooklyn has acquired an exclusive worldwide license to develop and commercialize certain cell-based therapies to treat cancer and rare blood disorders, including sickle cell disease, based on the patented technology and know-how of Factor and Novellus.

"We believe co-locating with Factor and Novellus will promote our capability to leverage our collaboration and further our objectives in developing a diversified portfolio of new, advanced therapeutics," said Howard J. Federoff, Brooklyn's chief executive and president.

Brooklyn's recently licensed platform from Factor and Novellus includes three novel technologies that the company expects to pursue at its new R&D location.

The first is a highly efficient mRNA cell reprogramming method. The second is a mRNA-based gene editing technology which can be applied to both allogeneic and autologous cells and which eliminates potential for off-target effects. The third is a proprietary tunable nanolipid delivery system that provides efficient non-viral vector-based delivery of mRNA ex vivo and in vivo to skin, brain, eye and lung tissue."


Write to Chris Wack at chris.wack@wsj.com



New York Yankees and Duke Basketball
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences